In septic rats, lenabasum reduced lung injury markers over 24 hours

Lenabasum attenuates CLP-induced sepsis-associated acute lung injury with coordinated modulation of redox balance and inflammation-resolution profile.

Naunyn-Schmiedeberg's archives of pharmacology • • Highly Relevant
🤖

AI Summary

This animal study tested whether lenabasum, a selective CB2 receptor agonist, could lessen sepsis-associated acute lung injury. Thirty male rats were assigned to sham, sepsis, two lenabasum-dose, or dexamethasone groups; treatment was given after sepsis induction, and outcomes were assessed 24 hours later. The researchers measured lung oxidative and antioxidant markers, blood markers of inflammation and resolution, and lung tissue injury.

Compared with untreated septic rats, both lenabasum doses reduced several inflammatory markers and the lung injury score, while shifting lipoxin A4 toward sham levels. The higher dose also reduced lung reactive oxygen species, increased reduced glutathione, and was associated with less tissue injury. These early findings suggest lenabasum may affect both inflammation and redox balance in this rat model. This abstract-based summary cannot establish that the effects depend on CB2 receptors or that lenabasum is effective or safe in people; the authors call for further preclinical study.

💡 Key Findings

1
In septic rats, both lenabasum doses reduced serum inflammatory markers and lung injury scores compared with the sepsis group.
Moderate
55%
2
At the higher dose, lenabasum reduced lung reactive oxygen species, increased reduced glutathione, and attenuated tissue injury.
Moderate
55%
3
Lenabasum shifted serum lipoxin A4 toward sham levels; whether its effects depend on CB2 receptors remains unestablished.
Moderate
55%

📄 Original Abstract

Sepsis-associated acute lung injury is a major experimental counterpart of human acute respiratory distress syndrome and involves inflammatory activation, redox imbalance, and structural lung damage. Lenabasum (JBT-101), a selective cannabinoid receptor type 2 (CB2) agonist, has shown anti-inflammatory and immunomodulatory properties in non-septic inflammation, but its effects in acute polymicrobial sepsis-associated lung injury remain poorly defined. This study evaluated lenabasum in a cecal ligation and puncture (CLP)-induced polymicrobial sepsis model during the acute 24-h phase, focusing on lung oxidative/antioxidant indices, the serum inflammation-resolution profile, and histopathological changes. 30 male Wistar rats were allocated to Sham, CLP, CLP + lenabasum 1 mg/kg, CLP + lenabasum 5 mg/kg, or CLP + dexamethasone 1 mg/kg groups. Interventions were administered intraperitoneally after sepsis induction. At 24 h, lung reactive oxygen species (ROS), malondialdehyde (MDA), and reduced glutathione (GSH) were measured. Serum tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), C-reactive protein (CRP), and lipoxin A4 (LXA4) were assessed as the inflammation-resolution profile. Lung injury was evaluated under blinded conditions using hematoxylin-eosin (H&E) staining and lung injury score (LIS). CLP increased lung ROS and MDA, decreased GSH, elevated serum TNF-α, IL-8, CRP, and LXA4, and induced histopathological lung injury. Both lenabasum doses reduced MDA, serum inflammatory markers, and LIS and shifted LXA4 toward Sham levels. At 5 mg/kg, lenabasum also reduced ROS, increased GSH, and attenuated histopathological lung injury. Lenabasum, particularly at 5 mg/kg, attenuated biochemical disturbances and histopathological lung injury at 24 h after CLP. These findings support further preclinical investigation of lenabasum, while the receptor dependence of its effects remains to be established.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.